Adverse Drug Reactions
Etanercept therapy for rheumatoid arthritis evaluated over 4 years
Published in Cancer Weekly, August 9th, 2005
"The tumor necrosis factor blocking agent etanercept is effective in the treatment of chronic inflammatory diseases. Previously published studies provided no evidence for an elevated frequency of severe adverse events under therapy," scientists in Germany reported.
"The present work documents efficacy and safety of long-term treatment with etanercept up to 4 years in 29 patients with rheumatoid arthritis in single German study center. Follow-up examinations were conducted at monthly intervals. The response was assessed in an intention-to-treat analysis (last...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-08-09)
More Articles from Cancer Weekly
- Apoptosis
Environmental UV-A and UV-B threshold doses for treating fibroblasts estimated - Cancer Registries
Cases reported to cancer registries hampered by time delays - Colon Cancer
Early life events related to later risk of colorectal cancer - Cyclophosphamide
Dermal exposure to cyclophosphamide in hospitals discussed - Osteoporosis
Attention focused on emerging oral complication from supportive cancer therapy - Alternative Medicine
Alternative approach to neurolysis is successful in blocking pelvic pain - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
